Atossa Therapeutics reports Q2 EPS (8c) vs. (5c) last year

“Positive momentum established last quarter has accelerated into the second quarter of 2023,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “We reached important enrollment milestones in each of our three ongoing Phase 2 trials, we strengthened our executive team with the addition of our board director Greg Weaver as our new CFO, and we further broadened intellectual property protection for our proprietary (Z)-endoxifen. Our balance sheet remains strong, and our focus remains squarely on completing our ongoing Phase 2 trials, designing Phase 3 protocols in coordination with the FDA and identifying the right partners to support pivotal trials and potential commercialization activities.”